Yahoo
NasdaqGM - Nasdaq Real Time Price USD

Xenon Pharmaceuticals Inc. (XENE)

36.27 +1.19 (+3.39%)
At close: October 20 at 4:00:00 PM EDT
Trade XENE on Coinbase
Chart Range Bar
Loading chart for XENE
  • Previous Close 35.08
  • Open 35.14
  • Bid 47.27 x 200
  • Ask 82.15 x 200
  • Day's Range 35.10 - 36.65
  • 52 Week Range 33.38 - 72.66
  • Volume 979,684
  • Avg. Volume 1,421,870
  • Market Cap (intraday) 3.512B
  • Beta (5Y Monthly) 0.60
  • PE Ratio (TTM) --
  • EPS (TTM) -4.74
  • Earnings Date Nov 2, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 72.43
  • Zacks Rating Neutral

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

www.xenon-pharma.com

358

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/20/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

XENE
19.08%
S&P 500 (^GSPC)
12.67%

1-Year Return

XENE
16.51%
S&P 500 (^GSPC)
14.51%

3-Year Return

XENE
9.12%
S&P 500 (^GSPC)
82.58%

5-Year Return

XENE
19.51%
S&P 500 (^GSPC)
70.02%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -110.74M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-100M
-80M
-60M
-40M
-20M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

46.00
72.43 Average
36.27 Current
90.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/18/2026
Analyst RBC Capital
Rating Action Maintains
Rating Outperform
Price Action Lowers
Price Target 81 -> 70

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    3.54B

  • Enterprise Value

    2.62B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    591.55

  • Price/Book (mrq)

    3.04

  • Enterprise Value/Revenue

    649.22

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -28.02%

  • Return on Equity (ttm)

    -43.62%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -409.2M

  • Diluted EPS (ttm)

    -4.74

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    930.69M

  • Total Debt/Equity (mrq)

    0.52%

  • Levered Free Cash Flow (ttm)

    -203.55M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

36.27 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: